Journal of Immunology Research

Research Article

Increased Interleukin-17F is Associated with Elevated Autoantibody Levels and More Clinically Relevant Than Interleukin-17A in Primary Sjögren’s Syndrome

Table 4

Serum levels of IL-17A and IL-17F in the presence and absence of clinical and laboratory manifestations of pSS patients.


Clinical and laboratory parameters	IL-17F (pg/mL)				IL-17A (pg/mL)
Clinical and laboratory parameters	Presence	Absence			Presence	Absence

Lymphadenectasis	12.68 (8.69, 20.08) ()	13.09 (10.00, 21.54) ()	−0.519	0.604	9.13 (7.88, 13.38) ()	9.75 (8.51, 10.36) ()	−0.268	0.789
Splenomegaly	12.68 (9.22, 22.69) ()	13.09 (9.60, 20.26) ()	0.164	0.87	9.75 (9.13, 11.59) ()	9.44 (7.88, 10.36) ()	1.618	0.106
Joint involvement	14.89 (9.87, 22.81) ()	12.68 (9.73, 19.98) ()	0.581	0.561	7.88 (7.88, 9.13) ()	9.75 (8.51, 10.98) ()	−2.443	0.015
Lung involvement	12.81 (10.00, 19.42) ()	13.22 (9.47, 27.27) ()	−0.525	0.6	9.44 (8.51, 10.59) ()	9.75 (7.88, 10.98) ()	−0.091	0.927
WBC ≤ 3.5 × 10⁹/L	17.13 (9.60, 34.15) ()	12.68 (9.73, 19.42) ()	1.535	0.125	9.75 (9.13, 11.36) ()	9.13 (7.88, 10.67) ()	1.128	0.259
Neutrophils ≤ 1.8 × 10⁹/L	15.16 (8.69, 27.27) ()	12.68 (10.00, 19.42) ()	0.521	0.602	9.75 (8.51, 10.97) ()	9.44 (7.88, 10.90) ()	0.386	0.998
RBC ≤ 3.5 × 10¹²/L	13.23 (9.47, 28.07) ()	12.95 (10.00, 18.85) ()	0.747	0.455	9.44 (7.88, 10.51) ()	9.75 (7.88, 11.21) ()	−0.679	0.497
Hb ≤ 110 g/L	12.14 (8.95, 17.99) ()	13.77 (9.87, 28.88) ()	−1.315	0.189	9.75 (7.88, 10.98) ()	9.59 (7.88, 10.51) ()	0.199	0.843
PLT ≤ 100 × 10⁹/L	12.95 (9.47, 22.07) ()	13.22 (10.00, 20.26) ()	−0.363	0.718	9.13 (7.88, 10.51) ()	9.75 (8.11, 10.98) ()	−0.183	0.855
IgA ≥ 4.5 g/L	13.77 (10.00, 29.61) ()	12.68 (9.47, 19.70) ()	0.353	0.725	9.75 (7.88, 11.59) ()	9.59 (7.88, 10.36) ()	0.927	0.362
IgG ≥ 16 g/L	15.44 (10.00, 27.44) ()	12.14 (9.21, 17.14) ()	2.06	0.039	9.13 (7.88, 10.98) ()	9.75 (8.19, 10.36) ()	−0.59	0.555
IgM ≥ 3 g/L	14.05 (10.13, 27.77) ()	12.68 (9.47, 19.42) ()	0.722	0.471	10.67 (9.13, 11.59) ()	9.44 (7.88, 10.36) ()	1.928	0.054
C3 < 0.78 g/L	14.33 (11.60, 22.69) ()	12.14 (9.47, 19.42) ()	1.158	0.247	9.75 (8.82, 11.59) ()	9.13 (7.88, 10.67) ()	1.586	0.113
C4 < 0.17 g/L	14.88 (12.14, 29.61) ()	11.60 (8.95, 18.99) ()	2.525	0.012	9.75 (9.13, 11.59) ()	9.44 (7.88, 10.36) ()	1.816	0.069
ESR ≥ 20 mm/h	13.49 (10.00, 22.90) ()	12.68 (9.47, 19.98) ()	0.522	0.603	9.75 (7.88, 11.51) ()	9.44 (7.88, 10.36) ()	0.996	0.321
RF ≥ 20 IU/mL	18.27 (11.06, 32.07) ()	10.53 (8.44, 13.77) ()	4.407	<0.001	9.75 (8.19, 11.59) ()	9.13 (7.88, 10.06) ()	2.637	0.01
Anti-SSA ≥ 200 RU/mL	14.88 (10.00, 25.03) ()	10.53 (8.69, 16.71) ()	2.375	0.018	9.59 (8.04, 10.36) ()	9.75 (7.88, 11.59) ()	−0.03	0.976
Anti-SSB ≥ 20 RU/mL	21.00 ± 19.95 ()	19.80 ± 21.39 ()	0.304	0.762	9.95 ± 4.16 ()	10.73 ± 3.77 ()	−1.019	0.311
ANA ≥ 1 : 320	14.88 (10.00, 29.61) ()	11.06 (9.47, 18.27) ()	2.132	0.033	9.44 (8.35, 11.13) ()	9.44 (7.88, 10.36) ()	0.29	0.772
ESSDAI ≥ 5	14.60 (10.53, 22.27) ()	10.53 (8.95, 19.42) ()	2.109	0.035	9.44 (7.88, 10.98) ()	9.75 (7.88, 10.36) ()	0.021	0.983